In a report issued on May 21, Gena Wang from Barclays maintained a Hold rating on BioCryst (BCRX), with a price target of $4. The company’s shares closed yesterday at $3.44, close to its 52-week low of $3.10.
According to TipRanks.com, Wang is a 5-star analyst with an average return of 19.6% and a 51.0% success rate. Wang covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Inc., Nightstar Therapeutics Limited, and Precision BioSciences Inc.
Currently, the analyst consensus on BioCryst is a Strong Buy with an average price target of $11.40.
See today’s analyst top recommended stocks >>
Based on BioCryst’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $31.05 million. In comparison, last year the company had a GAAP net loss of $25.78 million.
Based on the recent corporate insider activity of 41 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of BCRX in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
BioCryst Pharmaceuticals, Inc. designs, optimizes and develops novel small molecule drugs that block key enzymes involved in the pathogenesis of diseases. Its drug candidates include rapivab, alpivab, rapiacta, peramiflu, BCX7353, BCX9930, BCX9250, Galidesivir, and Mundesine. The company was founded in 1986 and is headquartered in Durham, NC.
